In this first episode of The Increasing Role of Urine Albumin-Creatinine Ratio (UACR) in Cardiovascular Care series, Dr. Ankeet Bhatt interviews Dr. Katherine Tuttle on UACR, its role in kidney disease, and the importance of screening. Listen to Dr. Tuttle provide an overview of the most recent evidence-based practices for UACR screening in cardiovascular disease risk assessment.

This podcast is supported by a grant from Boehringer Ingelheim. Visit the course page to learn more about the role of UACR in cardiovascular care.

This episode of CardiaCast will feature a discussion on the treatment of atherosclerotic cardiovascular disease (ASCVD) risk – from lifestyle to advanced therapies, led by Dr. Maya Safarova. The conversation covers lifestyle "therapy", the treatment algorithm for primary and secondary prevention, and what's on the horizon for ASCVD.

This podcast is supported by Esperion, Merck, and Novartis.

The second episode of the Increasing Role of UACR in Cardiovascular Care series focuses on the most recent evidence-based guidelines for elevated UACR and related cardiovascular (CV) conditions. Dr. Ankeet Bhatt interviews Dr. Nihar Desai on key terminology for albuminuria and discuss CV conditions associated with UACR as a biomarker.

This podcast is supported by a grant from Boehringer Ingelheim. Visit the course page to learn more about the role of UACR in Cardiovascular Care.

In this final episode of the Increasing Role of UACR in Cardiovascular Care series, Drs. Ankeet Bhatt and Brendan Neuen will break down why UACR screening is one of the most powerful yet underused tools for identifying early cardiovascular risk. Together, they examine the latest evidence on therapies and lifestyle strategies that reduce albuminuria, discuss their impact on kidney and cardiovascular risk, and highlight practical considerations for integrating these approaches into everyday clinical care. This podcast is supported by a grant from Boehringer Ingelheim. Visit the course page to learn more about the role of UACR in Cardiovascular Care.

This episode of CardiaCast will feature a discussion on risk assessment and the treatment of hypertriglyceridemia.

This podcast is supported by Esperion, Merck, and Novartis.

This episode of CardiaCast will feature a discussion on risk assessment and genetics in the prevention of cardiovascular disease.

This podcast is supported by Esperion, Merck, and Novartis.

This episode is part of ACC's ongoing initiative to recognize the risks and tackle management of Hypertriglyceridemia (HTG) and Severe Hypertriglyceridemia (sHTG). Drs. Michael Miller and Monica Aggarwal review and emphasize the need to understand the multifactorial and genetic causes of HTG and sHTG, as well as the associated risks of pancreatitis and ASCVD.

This podcast is part of the ACC's Hypertriglyceridemia and Cardiovascular Health: Recognizing Risks and Tackling Management initiative, supported by Ionis Pharmaceuticals.

This episode is part of ACC's ongoing educational initiative to enhance the recognition, diagnosis, and management of paroxysmal supraventricular tachycardia (PSVT). Faculty review contemporary acute treatment approaches, including established therapies, recent advances, and first-line emergency department strategies with attention to efficacy and safety. The discussion also addresses management of refractory or recurrent cases, decision-making across diverse patient populations and care settings, and criteria for hospital admission versus discharge. Additionally, it provides practical guidance on patient education, symptom recognition, and selecting treatments that balance effectiveness, safety, convenience, and patient confidence.

This podcast is part of the ACC's educational initiative on PSVT, supported by an independent educational grant from Milestone Pharmaceuticals Inc. Click here to learn more.